Mergers & Acquisitions ·
Lexeo completes acquisition of Mantle for $5.3M upfront plus up to $15M in contingent payments
LXEOLexeo Therapeutics, Inc.
On September 29, 2026, Lexeo Therapeutics completed its acquisition of Mantle Therapeutics via a merger with a wholly-owned subsidiary. The transaction consideration included an aggregate upfront payment of $5.3 million in cash and $3 million in Lexeo common stock for outstanding Mantle shares. Additional contingent payments include a potential one-time cash payment of $1 million and up to $12 million in milestone payments over 12 years, payable in cash or equity based on development and regulatory achievements. Lexeo Therapeutics operates in the biotechnology industry.